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Background: The non-specific bronchial hyper-responsiveness reported in mild to moderate
COPD is usually attributed to reduced airway calibre accentuating the effect of airway smooth
muscle shortening. We hypothesized that in more severe COPD the fall in forced expiratory
volume in 1 second (FEV1) seen during methacholine challenge would result from an increase
in residual volume and decrease in vital capacity rather than an increase in airways resistance.
Methods: Twenty-five subjects with moderate to severe COPD and 10 asthmatic subjects had
spirometry and oscillatory mechanics measured before methacholine challenge and at a 20%
fall from baseline post challenge (PC20FEV1).
Results: In the COPD subjects median PC20 was 0.35 mg/mL. Comparing baseline to PC20 there
were significant falls in forced vital capacity (FVC) (2.91 vs. 2.2 L; p < 0.001), slow vital
capacity (3.22 vs. 2.58 L; p < 0.001) and IC (2.21 vs. 1.75 L; p < 0.001) without change in
FEV1/FVC ratio (0.52 vs. 0.52; not significant) or in total lung capacity where this was
measured. Total respiratory system resistance (R5) was unchanged (0.66 vs. 0.68; not signifi-
cant) but total respiratory system reactance decreased significantly (0.33 vs. 0.44;
p < 0.001). In contrast, the asthmatics became more obstructed and showed a proportionally
smaller fall in lung volume with increase in R5 (0.43 vs. 0.64; p < 0.01).
Conclusions: In moderate to severe COPD the fall in FEV1 with methacholine is mainly due to
increases in residual volume, which may represent airway closure and new-onset expiratory
flow limitation.
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Non-specific bronchial hyper-responsiveness (BHR) is a key
finding in untreated bronchial asthma1 and is identified by
an excessive increase in airways resistance in response to
an agonist agent. This response is principally due to
increased airway smooth muscle activation which may
related to an infiltration of mast cells within the muscle.2
In contrast, much less is known about BHR in chronic
obstructive pulmonary disease (COPD)3 although reports
indicate that BHR is common in smokers with mild to
moderate COPD despite their relatively well preserved
lung function.4 In more severe disease the increase in BHR
is usually attributed to an excessive reduction in airway
calibre which amplifies the effect on expiratory flow for
any given degree of airway narrowing.5,6
BHR can be assessed by using a body plethysmograph to
measure the change in airways resistance although in
clinical practice the forced expiratory volume in 1 second
(FEV1) is normally used as a surrogate for airways resis-
tance.5 This is more convenient in COPD patients whose
increased mechanical time constants can make plethys-
mographic recording during panting unreliable7 and who
can produce reproducible FEV1 manoeuvres, even when
their lung function has acutely worsened.8 In severe COPD
there are considerable data addressing reducing broncho-
motor tone with bronchodilator drugs; an effect that
results from a reduction in lung volume rather than an
increase in airway resistance.9e11 Conversely there is little
data examining increase in bronchomotor tone with inhaled
non-specific agonists such as methacholine and it is not
known whether a fall in FEV1 occurs because of an increase
in static lung volume rather than increased airways resis-
tance. In this group of patients onset of expiratory flow
limitation and/or change in airway closure may explain an
increase in static lung volume.
We hypothesized that a change in the static lung
volume would not be accompanied by a substantial
increase in airways resistance but would mainly be due
to increase in residual volume and decrease in vital
capacity. To test this hypothesis we measured spirom-
etry and oscillatory lung mechanics in a group of stable
COPD patients inhaling methacholine until the FEV1 fell
by 20% of its baseline value. To validate the use of
oscillatory mechanics during challenge testing, we
repeated the protocol in a convenience sample of adult




Twenty-five patients with moderate COPD were recruited
from University Hospital Aintree, Liverpool. All were
45 years or older and met conventional diagnostic criteria
for COPD.12,13 COPD had been diagnosed in later life with
no prior history of asthma or atopy. All were or had been
cigarette smokers, with a minimum of 20-pack-year
exposure. Subjects had to have a pre-bronchodilator FEV1
of >1 litre and 40% predicted to participate in the studybut none had previously undergone bronchial challenge
testing.
All testing was performed on the same day. Short-acting
bronchodilator medication was withheld for at least 6 h and
long-acting bronchodilator medication and inhaled corti-
costeroids for 24 h. No subject was using tiotropium
bromide when studied and none had exacerbated or taken
antibiotics or oral corticosteroids in the previous 6 weeks.
South Sefton Research Ethics Committee approved the
research protocol and all participants gave written
informed consent.
Pulmonary function measurements
All equipment was calibrated before the testing according
to manufacturer’s instructions and the impulse oscillometry
system was checked against reference impedances of 0.1
and 0.2 kPa/L/s. Testing met American Thoracic Society/
European Respiratory Society Task Force recommenda-
tions14,15 and was performed in the same sequence for each
patient. Impulse oscillometry measurement of total respi-
ratory system resistance, reactance and impedance was
performed first followed by slow vital capacity and inspi-
ratory capacity and then, in seven subjects, measurement
of thoracic gas volume and hence total lung capacity and
residual volume by body plethysmography. This was fol-
lowed by measurement of airway resistance and specific
conductance by body plethysmography and finally flow
volume loops from which FEV1 and forced vital capacity
(FVC) were derived. The effect of deep inspiration was
minimized by use of rest periods and previously published
predicted values were used.16-17
Spirometry was derived from flowevolume loops
measured using a pneumotachograph attached to a body
plethysmograph (Model 1085Di, Medical Graphics Corpora-
tion, Minnesota, USA). After a period of tidal breathing
subjects were instructed to inhale to total lung capacity
and then exhale as quickly and forcefully as possible to
residual volume and then inhale back to tidal volume.
Exhalation was continued until complete lung emptying and
an absence of further flow. The FEV1 and FVC were derived
from these loops. At least three technically acceptable
efforts were made (showing FVC measurements within
150 mL) and the highest FEV1 and FVC were recorded.
To measure slow vital capacity (SVC) and inspiratory
capacity (IC) subjects completed four tidal breaths, inhaled
to total lung capacity and then exhaled slowly to residual
volume. Exhalation was continued until complete lung
emptying and an absence of further flow. The procedure
was repeated on at least three occasions until the two
largest SVC values were within 150 mL. The effort con-
taining the largest SVC was recorded.
In seven subjects total lung capacity (TLC) was also
measured using a body plethysmograph at a panting
frequency of 1e1.5 Hz. Thoracic gas volume (TGV) was
measured directly and TLC was derived as the sum of TGV
and the inspiratory capacity. Residual volume (RV) was
calculated by subtracting slow vital capacity from TLC.
Total respiratory system resistance at 5 Hz (R5), reac-
tance (X5) and impedance (Z5) were measured using the
technique of impulse oscillometry (Master Screen Impulse
Oscillometry, Erich Jaeger, Hoechberg, Germany). The
Table 1 Baseline characteristics of the 25 COPD subjects







Age (years) 64 (8) 34 (8)
Current/Ex/Non-smokers (n) 17/8/0 0/0/10
Pack years 66 (32) 0




FEV1 (L) 1.51 (0.3) 3.9 (0.6)
FEV1% predicted 56.0 (12.8) 93.7 (13.3)
FVC (L) 2.91 (0.89) 5.3 (0.9)
FVC % predicted 83.1 (21.9) 103.0 (9.8)
FEV1/FVC 0.52 (0.1) 0.76 (0.06)
IC (L) 2.21 (0.65) 4.16 (0.85)
IC % predicted 74.3 (13.9) 110.1 (17.7)
R5 (kPa/L/s) 0.66 (0.19) 0.43 (0.15)
R5% predicted 202 (54) 158 (49)
PC20 of methacholine
(mg/mL)
0.57 (0.41) 1.77 (1.96)
Data shown as mean (standard deviation).
Spirometry after methacholine in COPD 537technique involves the application of small pressure oscil-
lations at the mouth and recording of reflected oscillation
pressure and flow. Measurements were made during tidal
breathing with the subject seated, wearing a nose clip with
cheeks supported. At least six tidal breaths were recorded
on at least three occasions. Breathing frequency was
monitored and controlled and sequences of breaths of
similar duration and volume selected both before and after
challenge testing.8 The mean value of these measurements
was noted. Reference values were calculated from previ-
ously published equations.17
Methacholine challenge test
Challenge testing was performed using a modified Cock-
croft method.18-19 Methacholine (Norton, Leicester, UK)
was freshly prepared in 0.9% saline and administered at
room temperature. Spirometry was recorded using
a bellows spirometry (Vitalograph, Buckingham, UK) and
baseline FEV1 stability was established by ensuring that
three FEV1 measurements did not vary by more than
200 mL.
Methacholine aerosol was administered in increasing
doses at concentrations of 0.1e32 mg/mL from a dosimeter
(Spira Electro 2 Inhalation Dosimeter, Haemnlinna, Fin-
land). Subjects inhaled from FRC to TLC at a flow rate of
0.6 L/s, using a flow gauge to ensure constant flow. After
inhalation of 250 mL the aerosol was released electronically
and inhaled by the subject for 2.5 s who then held their
breath for 10 s. Five aliquots inhaled in rapid succession
constituted a single challenge dose.
FEV1 was recorded 60 s after each dose of methacholine
until it fell by more than 20% of baseline or 32 mg/mL
methacholine was administered. When this occurred the
FEV1 manoeuvre was repeated to confirm the value. All
pulmonary function tests were then repeated in the same
order as before challenge. The PC20dthe dose of meth-
acholine at which a fall in FEV1 of 20% from baseline was
achieveddwas determined by linear interpolation as were
all post-challenge values, which are quoted at PC20.
Preliminary trials suggested that tests performed at PC20
needed to be completed in less than 10 min after the
administration of that methacholine challenge dose. If
necessary testing was interrupted after this time and
spirometry repeated every 10 min until the challenge dose
had worn off, then a further challenge dose was adminis-
tered. Once spirometry confirmed that the PC20 FEV1 had
again been reached any outstanding measurements were
completed.
Asthmatic subjects
A convenience sample of 10 asthmatics was recruited to
demonstrate the ability of oscillometry to detect changes
in respiratory system mechanics. Asthma was diagnosed
according to Global Initiative for Asthma (GINA) criteria1
and subjects had normal spirometry at baseline recording.
These patients had minimal symptoms, were taking no
more than 800 mg beclomethasone or equivalent dose of
other inhaled steroids, and none had smoked. All asthmatic
subjects provided written informed consent and underwentthe same protocol as the subjects with COPD except for the
plethysmographic measurements.
Analysis
The absolute and percentage predicted values at baseline
were compared with values at PC20 dose using Student’s t-
tests (where data were normally distributed), and Manne
Whitney U-test and Wilcoxon tests (where data was non-
parametric). Group data are presented as mean (standard
deviation). Statistical significance was set at a p value of
<0.05.
Results
Baseline characteristics of the 25 COPD subjects and the
10 asthmatic subjects are shown in Table 1. During chal-
lenge testing all COPD subjects reached a PC20FEV1 at
a dose of methacholine below 2 mg/mL. Median PC20 was
0.35 mg/mL with a range from 0.08 to 1.78 mg/mL.
Data before and after challenge testing in the 25 COPD
subjects are shown in Table 2. At PC20 mean FEV1 fell from
1.51 L to 1.21 L (p < 0.001). This was accompanied by falls
in FVC (mean 2.91 to 2.25 L; p < 0.001), SVC (mean 3.22 to
2.58 L; p < 0.001) and IC (mean 2.21 to 1.75 L; p < 0.001).
The reduction in IC was closely related to the fall in SVC
(rZ 0.86, p < 0.001). The FEV1/FVC ratio was unchanged
at PC20 (0.52 pre vs. 0.53 post; pZ not significant)
(Figure 1).
It was initially assumed that TLC would be unchanged
after challenge as demonstrated previously,20,21 therefore,
it was only measured pre- and post-challenge in 7 subjects.
Table 2 Change in spirometry, lung volume and lung
mechanics, measured by impulse oscillometry and body






FEV1 (L) 1.51 (0.3) 1.21 (0.3) p < 0.001
FEV1% predicted 56 (12.8) 43 (11.5) p < 0.001
FVC (L) 2.91 (0.89) 2.25 (0.65) p < 0.001
FEV1/FVC ratio 0.52 (0.10) 0.53 (0.1) NS
SVC (L) 3.22 (1.03) 2.58 (0.88) p < 0.001
IC (L) 2.21 (0.65) 1.75 (0.49) p < 0.001
R5 (kPa/L/s) 0.66 (0.19) 0.68 (0.16) NS
R5% predicted 202 (54) 212 (64) NS
Z5 (kPa/L/s) 0.73 (0.25) 0.81 (0.21) p < 0.001
Z5% predicted 219 (74) 246 (65) p < 0.001
X5 (kPa/L/s) 0.33 (0.22) 0.44 (0.22) p < 0.001
Data shown as mean (standard deviation). Mean predicted
X5Z 0.04 kPa/L/s.
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differ from the overall population. TLC was unchanged
(7.37 to 7.39; pZ not significant) while RV increased (4.34
to 4.89; p < 0.03) significantly even in this small number of
subjects.
Change in measures of total respiratory system resis-
tance, reactance and impedance after methacholine chal-
lenge testing is also shown in Table 2. The total respiratory
system resistance at 5 Hz (R5) of the COPD patients was
considerably raised at baseline and unchanged post chal-
lenge (0.66 vs. 0.68 kPa/L/s; pZ not significant). Total
respiratory system reactance (X5) was markedly decreased
at baseline and a further significant reduction was seen
post challenge (0.33 vs. 0.44 kPa/L/s; p < 0.001). Total
respiratory system impedance (Z5) was raised at baseline
and increased further with challenge (0.73 vs. 0.81
kPa/L/s; p < 0.001).
Despite a narrow range of disease severity there was
a relationship between PC20 and FEV1 expressed asFigure 1 Change in FEV1/FVC ratio with bronchial challenge
in 25 subjects with COPD.a percentage of predicted value (rZ 0.55, pZ 0.005) as
well as FEV1/FVC ratio (rZ 0.4, pZ 0.06) but not absolute
FEV1 measured in litres (rZ 0.18, pZ 0.4). There was no
significant relationship between PC20 and any other
measurement of lung function.
Data from the asthmatic subjects are presented in
Table 3. In these subjects the median PC20 was 1.10 mg/mL
(range 0.24e6.8 mg/mL). The asthmatic subjects became
obstructed after challenge with a fall in the FEV1/FVC ratio
falling (0.76 pre vs. 0.66 post; p < 0.01). No statistical
comparison was made between the COPD group and the
asthma group but contrasting the results change in lung
volumes was smaller in the asthmatic subjects than in the
COPD subjects expressed as a percentage predicted
changedFVC decreasing by 660 mL (23% baseline) in
COPD subjects against 710 mL (13% baseline) in asthmatic
subjects, IC decreasing by 460 mL (21% baseline) in
COPD subjects against 410 mL (10% baseline) in asthmatic
subjects.
At baseline the asthmatic subjects had impulse oscill-
ometry readings, which were nearer predicted values and,
when contrasted with the COPD subjects, they had lower
total respiratory system resistance, reactance and
impedance. However, after challenge significant changes
in measures of airway resistance were seen in the asth-
matic subjects. The change seen in R5, X5 and Z5 were
greater in the asthmatic subjects and post challenge the
recordings were indistinguishable from those of the COPD
patients.
Discussion
Bronchial hyper-responsiveness is a cardinal feature of
bronchial asthma and its interpretation is relatively
straightforward when baseline airway calibre is normal.
However, in COPD this is by definition not the case and
several factors make interpretation difficult. These include
differences in the pattern of aerosol deposition from the
dosimeter,22 the site of airflow obstruction,23 the prior
volume history before the test manoeuvre, particularly the
need for a maximum inspiration,24,25 and local factorsTable 3 Change in spirometry, lung volume and lung
mechanics measured by impulse oscillometry after bron-





FEV1 (L) 3.90 (0.8) 3.06 (0.6) p < 0.01
FEV1%predicted 93.7 (13.3) 73.5 (11.4) p < 0.01
FVC (L) 5.34 (1.1) 4.63 (0.9) p < 0.01
FEV1/FVC ratio 0.76 (0.06) 0.66 (0.06) p < 0.01
IC (L) 4.16 (0.85) 3.75 (0.66) p < 0.01
R5 (kPa/L/s) 0.43 (0.16) 0.64 (0.16) pZ 0.002
R5% predicted 158 (49) 239 (61) pZ 0.002
Z5 (kPa/L/s) 0.42 (0.19) 0.81 (0.22) p < 0.001
Z5% predicted 141 (61) 268 (73) p < 0.001
X5 (kPa/L/s) 0.15 (0.09) 0.35 (0.16) p < 0.001
Data are presented as mean (standard deviation). Mean pre-
dicted X5Z 0.01 kPa/L/s.
Spirometry after methacholine in COPD 539related to airway wall thickening26,27 and airway paren-
chymal interdependence.28 Our data add a further factor to
this list by showing that the change in FEV1 in patients with
more severe COPD during bronchial challenge is determined
primarily by change in vital capacity and residual volume
rather than increase in respiratory resistance. These data
appear to confirm an earlier prediction made in patients
with less severe airflow obstruction that heterogeneity of
airways obstruction would lead to airway closure and an
increase in residual volume.29 In patients with more severe
COPD these changes in airway closure can explain much of
the fall in FEV1 following methacholine challenge.
During the challenge there was an overall proportionate
reduction in both FEV1 and FVC, the ratio of these values
remaining constant throughout the test. Hence the fall in
FEV1 was largely due to an increased residual volume rather
than any substantial increase in airways resistance
assuming TLC after challenge remained constant, as has
been reported in asthmatics during similar challenge
testing.20,21 We only measured TLC in 7 subjects primarily
because it had been shown previously not to alter during
challenge but also due to difficulties in obtaining reliable
and reproducible results in this population. The charac-
teristics and response to challenge in these 7 subjects was
indistinguishable from the overall population. This pattern
of change was still seen when the slow vital capacity data
was substituted for the forced vital capacity. The absolute
change in FEV1 at PC20 was significantly greater than the
known reproducibility of FEV1 in COPD patients
30 and so was
unlikely to have arisen by chance. Overall, these data in
COPD could be compatible with onset of expiratory flow
limitation and/or closure of previously emptying lung units
without a substantial change in the expiratory resistance of
those still contributing to expiratory flow. Change in expi-
ratory flow limitation and airway closure is likely to relate
to loss of lung parenchyma and airway attachments, airway
thickening and fibrosis, and inflammatory changes in the
airways. The mechanism of airway reactivity in COPD has
been discussed previously.3
Although the FEV1/FVC ratio is unchanged in the overall
population there is variability of response, as illustrated in
Figure 1. This variability is consistent with previously pub-
lished large series of COPD patients undergoing broncho-
dilator reversibility testing where there is also an overall
lack of change in FEV1/FVC.
31,32 Bronchodilator drugs have
been shown to be effective primarily by reduction in lung
volume and bronchomotor tone.9e11 The variability seen is
likely to reflect the pathophysiological variability seen in
any COPD population selected because of their disease
phenotype rather than any particular physiological
characteristic.
Our measurements of oscillatory mechanics are
compatible with changes produced primarily by increases in
lung volume. We measured total respiratory system resis-
tance and reactance at 5 Hz together with inspiratory
capacity in all our subjects. These allowed us to avoid the
difficulties associated with plethysmographic measure-
ment in patients with more severe airflow obstruction
similar to those in whom a volume-related bronchodilator
effect has been reported. Data from the unselected
asthmatics were included to show that the measurements
made were sufficiently sensitive to detect change withbronchoconstriction. Hence, in asthmatic subjects with
normal or near normal lung function changes in the
FEV1/FVC ratio and oscillatory mechanics, in particular
respiratory system resistance, occurred during methacho-
line challenge despite a change in vital capacity. The total
respiratory system reactance was greater after challenge
in the COPD patients. This might reflect the increased
operating lung volume but in the context of COPD we
speculate this is due to the combined effects of an
increased expiratory reactance with the onset of flow
limitation33 and an increased inspiratory reactance, which
is known to reflect transpulmonary resistance.34 Unfortu-
nately the commercial system available to us at the time
of this study could not partition the oscillatory signals into
inspiratory and expiratory components and doing so would
be helpful in distinguishing which of these processes was
contributing more to the observed changes, in particular
measurement of change in expiratory flow limitation. In
the small number of subjects where there was a modest
increase in total respiratory resistance this likely reflects
small airway narrowing, and the compression effect of
hyperinflation and air trapping.
The failure of the total respiratory system resistance to
change significantly in COPD could reflect a ceiling effect of
the measurement, although this appears unlikely as higher
R5 values are routinely recorded in children.
35 Total respi-
ratory system resistance was measured at a frequency of
5 Hz as this reflects resistance due to large and small
airways and minimizes pressure losses due to upper airway
shunt compliance, a factor unlikely to change significantly
during methacholine challenge. To reduce the effect of
upper airway shunt compliance further the patient’s head
and cheeks were supported during each measurement.
Additionally data in COPD patients have been published
previously at 5 Hz, making possible comparison with other
studies.8,36,37 Our data did not control for the potential
effect of deep inspiration on the response to the agonist in
the COPD patients, although recent data did not find such
a response in COPD patients.2 Given the very different
pattern of physiological change seen here from that in
normal subjects we feel that this is unlikely to have been
a major confounding factor. Breathing pattern and
frequency was carefully controlled before and after chal-
lenge to ensure this did not contribute to the changes
observed. Attempts to measure airway resistance and
specific conductance after bronchial challenge using body
plethysmography were unsuccessful as measurements were
not reproducible and were unreliable, as has been
described previously.38
In summary, our data have shown a high prevalence of
bronchial hyper-responsiveness assessed spirometrically in
patients with severe COPD, in keeping with the findings in
milder disease. In our patients the fall in FEV1 was due to
a change in vital capacity and consequently residual volume
after challenge, which could occur due to the onset of
expiratory flow limitation and/or airway closure. Some
increase in transpulmonary resistance appears likely
although we cannot at present determine the magnitude of
this effect. The change in static lung volume was paralleled
by a significant reduction in inspiratory capacity compa-
rable to that reported at the end of exercise39 or during
hospitalization for COPD.8 The ability of low concentrations
540 P.P. Walker et al.of an inhaled agonist to produce clinically relevant physi-
ological changes in lung volumes may help explain the
symptomatic deterioration experienced by some patients.Conflict of interest statement
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